Michael R. Lewis, Ph.D.

Associate Professor

Department of Veterinary Medicine & Surgery

Department of Radiology

Nuclear Science & Engineering Institutes

Phone:     (573) 814-6000, ext. 53703

Fax:           (573) 814-6551

Email:       LewisMic@missouri.edu

Office Address:    Harry S. Truman VA Hospital

                                 800 Hospital Drive – Research

                                 Columbia, MO  65201-5275
 

Mailing Address:   Department of Veterinary Medicine & Surgery

                                  College of Veterinary Medicine

                                  900 East Campus Drive

                                  University of Missouri-Columbia

                                  Columbia, MO 65211

Research Areas:   Radiopharmaceutical Chemistry, Radiopharmaceutical Biology

Education: B.S., Chemistry, University of North Carolina, Chapel Hill, 1984

                     M.S., Chemistry, California Institute of Technology, 1988

                     Ph.D., Biological Sciences, City of Hope Graduate School of Biological Sciences, 1997
                     NIH Postdoctoral Fellow, Washington University School of Medicine, 1997-2000

Research Description:

Our research program focuses on the development, evaluation, and application of metal-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of cancer in veterinary and human patients.  One of our projects involves the development of a radiolabeled immunotoxin for targeted multi-modality therapy of breast, lung, and prostate cancer.  A second project will evaluate radiolabeled pretargeting agents for multi-step radioimmunotherapy of colon and prostate cancer.  The third project involves the design, synthesis, and evaluation of radiopharmaceuticals for diagnostic imaging of oncogene expression in lymphoma and lung, gastrointestinal, and pancreatic cancers.  There are several advantages to evaluating tumor-targeting radiopharmaceuticals in veterinary patients, including the availability of more realistic animal models, patients with minimal treatment history, reduced regulatory burden, and shorter study endpoints.  This process facilitates translational research leading to human clinical trials.

Honors and Awards:

 

B.S. Degree with Highest Honors in Chemistry (UNC)
DuPont Resident Research Participant Award (UNC)
The Venable Medal Senior Chemistry Award (UNC)
Earle C. Anthony Special Institute Fellowship (Caltech)
National Science Foundation Graduate Fellowship (Caltech)
U.S. Army Breast Cancer Research Program Predoctoral Fellowship, "Gold Standard" Award (City of Hope)
National Institutes of Health Individual National Research Service Award,
National Cancer Institute (Washington University) National Institutes of Health Study Section Reviewer,
Oncological Sciences Initial Review Group, National Cancer Institute (MU):

 

 

Selected Publications:

Mohsin H, Jia F, Sivaguru G, Hudson MJ, Shelton TD, Hoffman TJ, Cutler CS, Ketring AR, Athey PS, Simón J, Frank RK, Jurisson SS, Lewis MR.  Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: Biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.  Bioconjugate Chem 17:485-492, 2006. [Abstract]

Balaji BS, Gallazzi F, Jia F, Lewis MR.  An efficient, convenient solid-phase synthesis of amino acid-modified peptide nucleic acid monomers and oligomers. Bioconjugate Chem 17:551-558, 2006. [Abstract]

Miller WH, Hartmann-Siantar C, Fisher D, Descalle MA, Daly T, Lehmann J, Lewis MR, Hoffman T, Smith J, Situ PD, Volkert WA. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biother Radiopharm 20(4):436-449; 2005  [Abstract]

Bryan JN, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ, Lewis MR. Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nucl Med Biol 32:851-858, 2005. [Abstract]

Essman SC, Lewis MR, Miller WH. Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: Implications for targeted radiotherapy of osteosarcoma. J Nucl Med 46:2076-2082, 2005.  [Abstract]

Lewis MR, Zhang J, Jia F, Owen NK, Cutler CS, Embree MF, Schultz J, Theodore LJ, Ketring AR, Jurisson SS, Axworthy DB.  Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol 31(2):213-23, 2004. [Abstract]

Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, Anderson CJ. Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. Vet Comp Oncol 2:82-90, 2004. [Abstract]

Lewis MR, Jia F.  Antisense imaging: and miles to go before we sleep? J Cell Biochem 90: 464-472, 2003 [Abstract]

Gallazzi F, Wang Y, Jia F, Shenoy N, Landon LA, Hannink M, Lever SZ, Lewis MR. Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene. Bioconjugate Chem 14:1083-1095, 2003 [Abstract]

Lewis MR, Jia F, Gallazzi F, Wang Y, Zhang J, Shenoy N, Lever SZ, Hannink M.  Radiometal-Labeled Peptide-PNA Conjugates for Targeting bcl-2 Expression: Preparation, Characterization, and in vitro mRNA Binding. Bioconjugate Chem 13:1176-1180, 2002. [Abstract]